文献速递甲状腺与颈部外科

甲状腺癌综合分子分型与肿瘤表型及癌症特异性结局的关联

Association of comprehensive thyroid cancer molecular profiling with tumor phenotype and cancer-specific outcomes.
PubMed 文献 · Surgery · 2022-10-20

该研究纳入578例术后接受ThySeq v3分子检测的甲状腺癌患者,按检测到的突变、融合、拷贝数改变和/或基因表达改变分为3个分子风险组,并与组织病理学和复发(生化或结构)进行关联。中位随访19个月,9.1%患者复发;多变量分析显示分子风险组-高级别较中级别复发风险更高(HR=4.0;95%CI 1.9-8.6;P<.001),中级别较低级别复发风险更高(HR=5.0;95%CI 2.0-12.5;P<.001)。

要点

  • 综合分子分型可将甲状腺癌分为低、中、高3个分子风险组。
  • 分子风险组-高级别与更差的组织病理学表型及更高复发风险相关。
  • 分子风险组-中级别复发风险也显著高于低级别。

核心结论

  • 基于现代综合基因分型可将甲状腺癌分为3个新的分子风险组,与组织病理学表型和短期随访复发相关。

研究设计与样本

  • 连续纳入578例甲状腺癌患者,均接受ThySeq version 3分子检测(术前细针穿刺或甲状腺切除标本),按检测到的突变、融合、拷贝数改变和/或基因表达改变分为3个分子风险组。

主要发现

  • 578例患者中,分子风险组-低、中、高级别分别占49.9%、37.5%、12.6%。
  • 中位随访19个月,9.1%患者复发。
  • 与低级别相比,中级别患者更年轻,更常见显微镜下甲状腺外侵犯、切缘受累和淋巴结病变。
  • 与中级别相比,高级别患者更年老,更常见肉眼甲状腺外侵犯和血管侵犯。
  • 多变量分析中,高级别较中级别复发风险更高(HR=4.0;95%CI 1.9-8.6;P<.001),中级别较低级别复发风险更高(HR=5.0;95%CI 2.0-12.5;P<.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular testing improves the diagnostic accuracy of thyroid cancer. Whether specific molecular testing results are associated with tumor phenotype or provide prognostic information needs further delineation. METHODS: Consecutive thyroid cancer patients after index thyroidectomy with ThyroSeq version 3 (Rye Brook, NY) molecular testing obtained on preoperative fine-needle aspiration or thyroidectomy specimens from patients with thyroid cancer were categorized into 3 molecular risk groups based on detected mutations, fusions, copy number alterations, and/or gene expression alterations and correlated with histopathology and recurrence, defined as biochemical or structural. RESULTS: Of 578 patients, 49.9%, 37.5%, and 12.6% had molecular risk group-low, molecular risk group-intermediate, and molecular risk group-high cancers, respectively. With a median 19-month follow-up, 9.1% patients recurred. Compared with molecular risk group-low, molecular risk group-intermediate cancers were diagnosed in younger patients and more often had microscopic extrathyroidal extension, involved margins, and nodal disease. Compared with molecular risk group-intermediate, molecular risk group-high cancers were diagnosed in older patients and more often had gross extrathyroidal extension and vascular invasion. In multivariable analysis, recurrence was more likely in molecular risk group-high cancers than in molecular risk group-intermediate (hazard ratio = 4.0; 95% confidence interval, 1.9-8.6; P < .001) and more likely in molecular risk group-intermediate than in molecular risk group-low (hazard ratio = 5.0; 95% confidence interval, 2.0-12.5; P < .001). CONCLUSION: Using modern comprehensive genotyping, the genetic profile of thyroid cancers can be categorized into 3 novel molecular risk groups that were associated with histopathologic phenotype and recurrence in short-term follow-up.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Liu JB, Ramonell KM, Carty SE, et al. Association of comprehensive thyroid cancer molecular profiling with tumor phenotype and cancer-specific outcomes. Surgery. 2022. PMID: 36272768. doi:10.1016/j.surg.2022.05.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。